What is Sequella?
Sequella is dedicated to developing innovative antibiotics, antifungals, and antiparasitics to address critical global health challenges. The company's primary focus is on tackling drug-resistant bacterial and fungal infections, with a particular emphasis on multidrug-resistant tuberculosis (TB), a disease affecting billions worldwide. With promising drug candidates like SQ109 and sutezolid having advanced through Phase 2 clinical trials, Sequella is positioned to deliver much-needed therapeutic solutions in an area of urgent unmet medical need. Their pipeline also extends to treatments for other severe infections, including those caused by Clostridium difficile and various parasitic agents.
How much funding has Sequella raised?
Sequella has raised a total of $11.9M across 11 funding rounds:
Debt
$2M
Multiple Rounds
$1.6M
Unspecified
$100K
Unspecified
$555K
Debt
$3.1M
Private Equity
$1.7M
Private Equity
$630K
Debt (2010): $2M, investors not publicly disclosed
Debt (2011): $1M featuring Easton Capital Partners
Unspecified (2011): $550K backed by Easton Capital Partners
Debt (2011): $50K with participation from Easton Capital Partners
Unspecified (2012): $100K led by Easton Capital Partners
Unspecified (2013): $555K supported by Easton Capital Partners
Debt (2014): $3.1M, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
Private Equity (2017): $630K, investors not publicly disclosed
Key Investors in Sequella
Easton Capital Partners
Easton Capital Investment Group manages approximately $200 million across three funds, focusing on investments ranging from $2 million to $7.5 million. They have strategic co-investment relationships that enable participation in larger funding rounds.
What's next for Sequella?
The substantial enterprise-level capital infusion and recent strategic investment signal a pivotal growth phase for Sequella. This financing is anticipated to fuel the advancement of its lead drug candidates through late-stage clinical trials, regulatory submissions, and eventual commercialization. The company's strategic focus on high-impact infectious diseases, particularly drug-resistant TB, positions it to capture significant market share and address a critical global health crisis. Future developments will likely involve expanding its therapeutic pipeline and forging strategic partnerships to enhance its market reach and impact.
See full Sequella company page
